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D 4.13 Adjuvant Therapy Mter Revascularization
D 4.13.1 Introduction
Vascular and endovascular procedures suffer a risk of failure, either early, intermediate, or late.
Several factors affect this risk, and the incidence differs considerably between various types of
procedures. The main causes of failure can be categorized as (I) early-technical flaws or low
flow or increased thrombogenicity; (2) intermediate (6-24 months)-intimal hyperplasia; and (3)
late-progression of atheromatous disease.
Regarding open vascular procedures, factors that affect failure are the use of autogenous versus
synthetic vascular conduits, endarterectomy versus bypass procedures, and the location of the
procedure, for example, an aortic procedure compared with a distal reconstruction. This also
relates to differences in the caliber of the recipient arteries, occlusive lesions in the inflow or
outflow vessels, and the capacity of the collateral circulation.
Bypass patency also depends on the caliber and length of graft to be used. Progression of dis-
ease and risk factors such as smoking and blood lipids have a major implication on patency. At
one extreme, an aortobifemoral graft with a perfect outflow carries at least a 90% l-year paten-
cy, whereas the corresponding figure for a prosthetic femorodistal bypass with restricted run-off
might be 30% or even less. Technical problems, encountered during surgery or caused by
surgery, also greatly influence the immediate outcome of the procedure. The same kind of fac-
tors presumably influence the outcome of endovascular procedures. However, some of these
procedures have only come into use recently, which means that less knowledge exists on the
incidence and magnitude of the problems.
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Current adjuvant pharmacological treatment aims to reduce either early failures due to thrombo-
sis, intermediate graft occlusions due to intimal hyperplasia, or further progression of atheroscle-
rosis. Even though vein grafts are at much less risk of developing occlusions than synthetic grafts,
it is reasonable to discuss them together because most of the expected problems are of the same
kind, though not of the same magnitude. Various pharmacological agents are in use to prevent
thrombosis. The two most important categories are antiplatelet therapyand anticoagulation.
Recently also, prostanoids and nitric oxide have been tried clinically. Although exerting
antiplatelet effects, these compounds are discussed separately from antiplatelet therapy.
D 4.13.2 Antiplatelet Therapy
Acetylsalicylic acid
Acetylsalicylic acid (ASA) has been recommended on its own merits for reducing thrombotic
events in all patients with PAD (see Recommendation 28, p 883). This discussion focuses on the
use of ASA to assist the patency of revascularization procedures. Acetylsalicylic acid has been
investigated in randomized clinical trials, either alone or in combination with dipyridamole. In a
1982 report, patients with PTFE grafts for either above-knee or below-knee femoropopliteal
bypass procedures were randomized to either placebo, ASA alone. or ASA plus dipyridamole,
starting preoperatively.1 For below-knee grafts, no difference was found between the groups,
whereas those patients on placebo undergoing an above-knee reconstruction had a significantly
worse outcome than those receiving ASA or ASA plus dipyridamole. In combined series with
autologous veins and PTFE grafts, no patency differences were seen with placebo versus ASA or
ASA plus dipyridamole treatment given postoperatively in two series.2,3
In a large series, 549 patients, all with a femoropopliteal autologous vein bypass, were random-
ized to treatment with either ASA plus dipyridamole or placebo.s Patients were followed-up for
3 years, and there were no differences in patency rates recorded between the groups.
Conversely, me Antiplatelet Trialists in their meta-analysis found mat not only survival but also
graft patency could be improved using ASA.5
A theoretical explanation for an early benefit of ASA is given in a study by Goldman et al,6 find-
ing a lower thrombogenicity index with ASA and dipyridamole treatment using 11lindium-
labeled platelets. Based on current knowledge, ASA is recommended for those undergoing
interventions. A Danish review recently concluded mat mere is evidence for lifelong treatment
with ASA after infrainguinal vascular reconstructions? The authors also recommended a rather
high dose (300-500 mg ASA daily).
Recommendation 96: Antiplatelets as a<ijuyant pharmacotherapy after revascularization
Antiplatelet therapy should be started preoperatively and continued as adjuvant phar-
macotherapyafter an endovascular or surgical procedure. Unless subsequently con-
traindicated, this should be continued indefinitely, Caution should be used in patients
in whom use of anticoagulants is proposed.
Tielopidine
Ticlopidine, as a more recent antiplate1et drug, has proved effective in preventing vascular com-
plications.f A reduced platelet uptake on aortobifemoral grafts has been shown.? A recently
published prospective, randomized, multicenter study has shown that ticlopidine compared with
placebo after femoropopliteal or femorotibial saphenous vein bypass procedures in 143 patients
increased both survival and 2-year patency of saphenous vein bypass grafts in the legs.I? Some
of the side effects of ticlopidine, such as thrombocytopenia.U do not appear to be present with
newer ADP inhibitors such as clopidogrcl.l-
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D 4.13.3 Anticoagulants
The use of unfracrionared heparin (UFH) during vascular surgery is a widespread routine.
Recently, it was shown that low-molecular-weight heparin (LMWH) is as effective an anticoagu-
lant as UFH during infrainguinal bypass surgeryl-' Conversely, UFH has been used more selec-
tively during the postoperative course. The main reason might be a risk of postoperative bleed-
ing and a need for careful monitoring of coagulation parameters. The development of LMWH
has changed this perspective considerably, and studies have pointed at beneficial effects of
LMWH in the postoperative management of infrainguinal bypass.
A randomized controlled study comparing LMWH with ASA and dipyridamole-e showed signif-
icantly better patency in the LMWH group, but restricted to patients with CLI. This study
combined results achieved with both synthetic grafts and vein grafts. It has been suggested that
the conclusions are less valid because only one fourth of the grafts were vein; the remaining
were various synthetic materials, and all patients received LMWH for the first week postopera-
tively, after which the randomized scheme started. In another randomized controlled trial com-
paring LMWH and unfractionated heparin, it was shown that LMWH was superior and as safe
as unfractionated heparin in prevention of early graft thrornbosis.lf
Oral coumarin seems to increase patient survival, but controversies exist as to whether graft
patency could be influenced. In two studies from Austria, it has been shown that graft patency
is improved in patients with saphenous vein grafts receiving oral anticoagulation. Both primary
graft patency and limb salvage were significantly increased.16,17 In the first of these two studies,
this effect was restricted to patients operated on for CLI. In this study, 12% of patients random-
ized to coumarin were withdrawn for bleeding complications. Contrary to these findings, a
Swedish study, including patients receiving either vein grafts or synthetic grafts, did not indicate
any better outcome in patients receiving oral anticoagulation during a 3-year follow-up.P The
place for coumarin as adjuvant therapy after revascularization procedures remains to be deter-
mined (see Critical Issue 30, p S200).
D 4.13.4 Other Drugs
Dextran
Dextran is able to reduce platelet uptake on graft surfaces'? and was shown to be beneficial dur-
ing follow-up of "difficult lower extremity revascularizations" utilizing either veins or synthetic
grafts. 20 The graft occlusion rate at 1 week was 20.5% in the control group and 6.9% (0%in
vein grafts) in the dextran 40 group. By the end of the trial, the overall advantage of dextran
40 was statistically significant at all times up to and including 1 month and in the subgroup
with umbilical vein or prosthetic grafts, significant benefit lasted up to 32 months. However,
there was no advantage in vein graft bypasses unless they were carried to crural arteries.s? The
latter has been confirmed in a recent single-center prospective randomized trial.21
Dextran has been used extensively in Sweden, bur there are few published studies that compare
dextran with other forms of treatment. Recently, dextran 70 was compared with LMWH for
distal vascular reconstructions. New data indicate few differences, except considerably more side
effects with dextran.s- Although anaphylactic reactions have been mitigated by pretreatment
with the hapten, other complications such as wound bleeding and vascular overload are not
uncommon unless a strict protocol is followed and certain categorical exclusions observed such
as recent myocardial infarction, congestive heart failure, and renal insufficiency, particularly in
patients with diabetes. On this basis, dextran 70 cannot be recommended as a routine measure
and should only be used in those distal bypasses in which there is a predictably high risk of early
thrombosis (eg, non-autogenous reconstructions or crural bypasses) and no contraindications.
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Prostanoids
Prostanoids such as the prostacyclin analog iloprost have antiplatelet effects but also have effects
on white cell aggregation and adhesion as well as on vasoconstriction. Flow increases in vein
grafts during distal vascular reconstructions after iloprost injection have been shown.23 In a
large European multicenter study on patients with eLI comparing iloprost and placebo in distal
vascular reconstructions using either vein grafts or synthetic grafts, no significant improvement
could be shown with respect to the I-year patency.-? Whether this failure could be attributed to
the short time of drug administration, only during the day of surgery and 2 subsequent days, is
uncertain but may be a possibility. Interestingly, synthetic grafts performed better during the
first month, when patients were treated with iloprost.
Nitric oxide
In a small series, nitric oxide has been administered during infrainguinal bypass surgery, result-
ing in an augmented graft flow and inhibition of depleted plasma antioxidants. Results on
patency have not yet b~en presented-f
D 4.13.5 New Approaches
Activation of the glycoprotein (GP)IIb/IIla on the platelet surface is the final pathway of
platelet aggregation, regardless of the initiating stimulus. Inhibitors of GPIIb/lIIa receptors
include monoclonal antibodies and peptidic as well as nonpeptidic synthetic specific receptor
blockers. Abciximab exchanges between and binds to platelets for as long as 2 weeks, whereas
synthetic GPIIb/IIla inhibitors block ex vivo platelet aggregation only a few hours after the end
of an infusion but havethe advantage of also being orally active. New ways to interfere with the
complex coagulation system abound. Direct inhibitors of thrombin is one of the recent pharma-
cological approaches being evaluated in clinical trials. Other approaches are synthetic inhibitors
of factors VIII, IX or X, tissue factor pathway inhibitors, or inactivated factor VIII.26,27,28
D 4.13.6 Adjuvant Therapy After Endovascular Procedures
For endovascular procedures, especially PTCA, anticoagulation has been advised, including oral
anticoagulation. However, in recent studies, the need for oral anticoagulation has been ques-
tioned.l? Vascular stents in the femoropopliteal region have been used without long-term antico-
agulation, and reasonably acceptable early and intermediate patency rates have been obtained.w
although other authors have routinely used coumarin. 30,31,32,33,34-,35 In a Swedish multicenter
study,patients were treated with ASA and dipyridamole or placebo after PTA of iliac and infrain-
guinal vessels. No differences were recorded between the groups with respect to the I-year
patency rate. 36
D 4.13.7 Swnmary of Adjuvant Therapy
Even though randomized controlled studies are not entirely convincing, there seems to be con-
sensus that adjuvant pharmacotherapy is needed to prevent graft thrombosis. Aspirin is the ther-
apy most used, administered in a dose of 75 or 160 rng daily, although the low-dose/high-dose
debate is not settled. In most of the trials suggesting protected patency, the higher dose of
aspirin was used.I. 2,3 Conversely, compliance may be a problem with the higher dose over time.
Whether LMWH should replace aspirin, for example, for infrainguinal bypass, is not established.
It seems important to start the treatment preoperatively. It seems reasonable to use the same
policy for endovascular procedures as for surgical procedures, and a regimen with ASA is
advised (see Recommendation 96, p S248).
D 4.13.8 Intimal Hyperplasia
Proliferation of smooth muscle cells causing hyperplastic growth, especially in the distal anasto-
mosis of a synthetic graft or in the anastomoses or body of a vein graft, is the main cause of
graft failure during a mid-term follow-up. Strict programs for graft surveillance give an opportu-
nity to treat the lesion before any deleterious clinical effect, but most importantly, measures to
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prevent this hyperplastic growth have to be found. A major question is whether drugs that may
reduce thrombogenicity are usable for this purpose as well. Drugs to be discussed are aspirin
and heparin, UFH or LMWH. Clinical effects of aspirin and dipyridamole were seen after
peripheral vascular surgery; however, with a short-term follow-up, this only proves an effect on
thrombus formarion .e?
Heparin (UFH ) has been shown to inhibit proliferation and migration ofsmooth muscle cells
even in vivo .38 In animal models, an effect on intimal hyperplasia has been evident, however,
any clinical benefit in humans has not been proved.s? It has been suggested that a continuous
heparin infusion has to be used and also that LMWH has a greater effect on native arteries than
on vein grafts .40,4 1 Another proposal is that very high doses of heparin are needed.P The study
reported above, intending to compare aspirin and LMWH, claimed a beneficial effect of
LMWH on intimal hyperplasia.I" This conclusion is not entirely evident, because the effect was
seen mostly in patients with severe ischemia, in which case an effect on thrombogenicity might
be as important as an effect on intimal hyperplasia. Several experimental models have been tried
to reduce intimal hyperplasia. Some of them are listed in Table 55 . In addition, radiation and
drug delivery from, or together with, implanted stents are under evaluation.43,44
Interesting ly, almost all drugs reported in Table 55 exert a positive effect in the respective
experimental model. Whether any of these findings will be possible to transfer to the human sit-
nation is too early to predict. Apparently, cholesterol reduction is an interesting possibility,
because it promises to reduce atherosclerosis, but apparently also hyperplastic growth. Calcium
channel antagonists, lipid-lowering drugs, and treatment of hypertension are all associated with
reduced progression of atherosclerosis, especially if combined with smoking cessation and exer-
cise. Whether this kind of treatment will also affect intimal hyperplastic growth has still to be
proved. Both early thrombosis and late hyperplastic growth are multifactorial events, and it
therefore would be most astonishing if one single drug could prevent them all. Concerning the
cells involved, white cells, and to a lesser degree, platelets, are crucial. Maybe there is a future in
drugs acting in different ways to reduce platelet activity. Synergistic effects have been shown
with drugs acting on different pathways, and a combination of cGMP- and cAMP-elevating and
cyclooxygenase-inhibiting drugs may be useful. Most certainly, there will also be techniques to
inhibit the effects of activated white cells participating in the inflammatory response.
Table 55: Compounds used in animal model experimental settings to reduce intimal hyperplasia
Compound
Naroparci/f 5
Scavengers46
L-argininef 7•48
Angiotensin-converting enzyme inhib ition 49
Cholesterol reducnonw
Keranserin'il
FGF saporin52
VEGF5 3
Cyclosporinse
Lazaroids55
Experimental setting
arte ria] injury
vein grafts
vein grafts
PTA
vein grafts
vein grafts
PTFEgrafts
vein gIT.fts
aortic transplant
vein grafts
Effect
+
+
+
+
+
+
+
+
+
Critical Issue 38: Agents to inhibit intimal hyperplasia
There is a need to determine the clinical efficacy of agents reported to inhibit intimal
hyperplasia in animal models. Because intimal hyperplasia is a major cause of failure of
both percutaneous and open surgical revascularization procedures, research aimed at its
prevention is of critical importance.
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D 4.14 Surveillance After Revascularization
D 4.14.1 Introduction
Despite a high likelihood of immediate success, all lower-extremity revascularization procedures
have a significant rate offailure over time (see also B 4.4, Surgery for Intermittent Claudication,
p S113). It is now well recognized that patency of the treated arterial segment is most effective-
ly preserved through surveillance programs that are capable of identifying flow-limiting lesions
before complete occlusion of the conduit or vessel,l,2,3,4 Revision offailing reversed saphenous
vein bypass grafts, for example, results in excellent long-term graft function, with assisted prima-
